Hindustantimes wants to start sending you push notifications. Click allow to subscribe

Oxygen support, anti coagulants, steroids mainstay of Covid-19 therapy, says govt

Hindustan Times, New Delhi | Byhindustantimes.com| Edited by Sabir Hussain
Jul 11, 2020 06:39 PM IST

The Health ministry said the pursuit of an effective treatment for Covid-19 has also resulted in repurposing of several drugs which are not a part of the main Clinical Management Protocol but have been indicated as “investigational therapies”.

The Indian Council of Medical Research (ICMR) and AIIMS, New Delhi have underlined that the standard care and treatment for mild, moderate and severe cases of Covid-19 described in the Clinical Management Protocol of Ministry of Health and Family Welfare (MoHFW), would be most effective in the absence of a cure for the disease.

In a video conference with states on Friday and a virtual meeting on “Covid Case Management by State/UT Centres of Excellence” the ICMR and AIIMS said the approach for treatment of Covid-19 is largely based on asymptomatic and supportive care, since there is no cure as yet. Based on severity of symptoms, Covid-19 can be categorised into three groups: mild, moderate and severe.

Hindustan Times - your fastest source for breaking news! Read now.

“For moderate and severe cases, adequate oxygen support, appropriate and timely administration of anticoagulants and widely available and inexpensive corticosteroids, in accordance with the protocol, can be considered to be the mainstay of Covid-19 therapy. For mild cases, which are nearly 80% of the total cases, Hydroxychloroquine (HCQ) has been recommended. The standard of care treatment strategies have shown to yield positive results,” the Health ministry said in a statement.

Click here for full Covid-19 coverage.

It also said the pursuit of an effective treatment for Covid-19 has also resulted in repurposing of several drugs which are not a part of the main Clinical Management Protocol but have been indicated as “investigational therapies”.

The ministry said these drugs can be used in specific sub-groups of patients on the basis of informed and shared decision making with the patient before prescribing these drugs.

“These drugs have still not been approved by the Drugs Controller General of India (DCGI) and are only permitted for restricted emergency use for Covid-19. The States as well as the Medical College hospitals designated as Centres of Excellence were reminded by ICMR and AIIMS that their indiscriminate use or use in conditions for which they are not desirable, may cause more harm than good.”

The states were also told that the available evidence for Remdesivir suggests that it may decrease the time for clinical improvement when used in moderate to severe cases.

“However, there have been no benefits in terms of reduced mortality. It has to be used with extreme caution due to its potential for serious adverse effects including liver and kidney injury. Similarly, for Tocilizumab studies have not shown any benefits in mortality reduction,” the ministry said.

It also warned against rampant use of the drug. “However, If used for patients with severe conditions, proper informed consent is required. Rampant use is to be discouraged since the effect of the drug is directed at the cykotine storm,” the health ministry said.

All the ‘investigational therapies’ are required to be carried out only in proper health care facilities where close monitoring of patients is possible so that potential complications can be managed.

During the video conference, the ICMR also stressed on high quality supportive care, including mental health counselling for patients and families, management of pre-existing illness and palliation of symptoms

Unveiling Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch now!

Get Current Updates on India News, Election 2024, Arvind Kejriwal News Live, Bihar Board 10th Result 2024 Live along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Start 14 Days Free Trial Subscribe Now
OPEN APP